- Raised $6.4M funding round, Aug 2021
- Raised $1.4M funding round led by PipelBiz, Jul 2023
- Raised $700k grant, Aug 2022
About
The cytokine storm is the most severe complication of a wide range of pulmonary and systemic diseases with an urgent unmet need, leading to more than 60M patients with 15M deaths per year.
Utilising two breakthroughs, CD24 (the drug), and Exosomes (the carrier), Nano24 has developed the next generation of immunomodulators proving to solve the cytokine storm. EXO- CD24 is the first clinically tested, IP protected, exosomal based drug derived from genetically manipulated human embryonic cells. As a platform, EXO-CD24 has the potential to address many unmet indications, such as ARDS, SEPSIS, Cardiogenic Shock and many more.
As a first step, Nano24 focuses on the ARDS market, which has no medical therapy, is responsible for 10-20% general admissions to ICU and causes 1.2 million deaths per year (similar to the world wide annual deaths from car accidents). After clinical trials phases Ib+IIa and IIb (dose finding study), the results showed extremely high success, with no deaths caused by the cytokine storm, duration of hospitalisation dramatically reduced and no any side effects.
Nano24 (formerly OBCTCD24) was established in June 2020, based on 25 years of knowledge and experience accumulated in the lab of Dr. Shapira and Prof. Arber.
Funding history · 4 rounds · $9.5M total
Q&A
- What is Nano24's primary focus in the medical field?
- Nano24 focuses on developing the next generation of immunomodulators to address the cytokine storm, a severe complication of various pulmonary and systemic diseases. Their initial focus is on the ARDS (Acute Respiratory Distress Syndrome) market.
- What is the core technology behind Nano24's drug development?
- Nano24 utilizes CD24 as the drug and Exosomes as the carrier to develop EXO-CD24, an exosomal-based drug derived from genetically manipulated human embryonic cells. This technology aims to solve the cytokine storm.
- When was Nano24 established and by whom?
- Nano24 was established in June 2020 by Prof. Nadir Arber and Dr. Shiran Shapira, building on 25 years of their accumulated knowledge and experience.
- What was Nano24's most recent funding round?
- In July 2023, Nano24 secured a funding round with PipelBiz as a lead investor.
- What is the total amount of funding Nano24 has raised to date?
- Nano24 has raised a total of $9,500,000 USD.
- What is the status of Nano24's product development?
- Nano24's product, EXO-CD24, is in the clinical trial stage, having completed phases Ib+IIa and IIb (dose-finding study) with reported high success rates.
- Does Nano24 hold any patents?
- Yes, Nano24 holds at least one patent for its technology.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nano24med.com/ |
|---|---|
| linkedin.com/company/70961582 |
Identifiers & details
| Former names | OBCTD24 |
|---|---|
| Founded | 2020-6 |
| Employees (exact) | 2 |
Radar intelligence
Web history (Wayback)
| Domain | nano24med.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|